Algernon Pharmaceuticals Inc
CNSX:AGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Algernon Pharmaceuticals Inc
Net Income (Common)
Algernon Pharmaceuticals Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Algernon Pharmaceuticals Inc
CNSX:AGN
|
Net Income (Common)
-CA$1.9m
|
CAGR 3-Years
34%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Profound Medical Corp
TSX:PRN
|
Net Income (Common)
-$42.6m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-13%
|
|
|
Perimeter Medical Imaging AI Inc
XTSX:PINK
|
Net Income (Common)
-CA$12.9m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Nanalysis Scientific Corp
XTSX:NSCI
|
Net Income (Common)
-CA$5.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Theralase Technologies Inc
XTSX:TLT
|
Net Income (Common)
-CA$4.4m
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
2%
|
|
|
Conavi Medical Corp
XTSX:CNVI
|
Net Income (Common)
-$16.2m
|
CAGR 3-Years
35%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
Algernon Pharmaceuticals Inc
Glance View
Algernon Pharmaceuticals Inc is a CA-based company operating in industry. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2016-02-01. Algernon Pharmaceuticals Inc. is a clinical stage pharmaceutical development company that is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough. The Company’s drug discovery approach is based on the concept of drug repurposing. Drug repurposing is the process of discovering new therapeutic uses for existing drugs. Its research and development (R&D) work are carried out by the Company’s Canadian subsidiary, Nash Pharmaceuticals Inc. (Nash Pharma). The Company’s lead compound is a drug called Ifenprodil, which is being developed for idiopathic pulmonary fibrosis (IPF) and chronic cough, as well as coronavirus disease of 2019 (COVID-19).
See Also
What is Algernon Pharmaceuticals Inc's Net Income (Common)?
Net Income (Common)
-1.9m
CAD
Based on the financial report for Nov 30, 2025, Algernon Pharmaceuticals Inc's Net Income (Common) amounts to -1.9m CAD.
What is Algernon Pharmaceuticals Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
30%
Over the last year, the Net Income (Common) growth was -433%. The average annual Net Income (Common) growth rates for Algernon Pharmaceuticals Inc have been 34% over the past three years , 30% over the past five years .
